On the contrary, in sections of the mammary sample taken 6 weeks after DMBA treatment, which showed histopathological changes, the CacyBP/SIP immunoreactivity was more prominent, present in a form of deposits in the cytoplasm of cancer cells (Fig. 2a, lower right panel). The gene discussed is CACYBP; the disease is cancer.